title: [Comparative research on anticancer activity between fresh and processed Gekko subpalmatus].
abstract: OBJECTIVE
  To investigate the anticancer activity of fresh and processed Gekko subpalmatus on mouse H22 hepatocellular in vitro and in vivo comparatively.
  
  
  METHODS
  In vitro, the effect of different concentration fresh and processed Gekko subpalmatus on proliferation of H22 cells were measured by Monotetrazolium (MTT) assay. Mouse transplanted hepatoma H22 model was established to evaluate the anti-tumor activity of fresh and processed Gekko subpalmatus. Rate of restraining tumor, index of thymus and spleen were calculated after 14 days' treatment.
  
  
  RESULTS
  In vitro, fresh and processed Gekko subpalmatus inhibited proliferation of H22 cells and the IC50 values were 8.53 mg/ml and 6.42 mg/ml. In vivo, the restraining tumor rates of fresh and processed Gekko subpalmatus each at the highest doses were 53.0% and 47.4%. Compared with those in CTX group, the indexes of thymus and spleen were markedly increased after all processed group's treatment. The indexes of the thymus increased after low dose fresh group's treatment. The indexes of the spleen of the moderate and high dose groups were higher than CTX group.
  
  
  CONCLUSIONS
  Fresh and processed Gekko subpalmatus show significant anti-tumor activity in hepatoma cells both in vitro and in vivo. The processed samples can improve the immunity of the mouse.
authors.affiliation: Department of Biological Pharmaceutics, School of Chinese Pharmacy, Beijing University of Traditional Chinese Medicine, Beijing 100102, China.
authors.forename: Xin-Nan
authors.initials: XN
authors.lastname: Hou
authors.forename: Di
authors.initials: D
authors.lastname: Geng
authors.forename: Ang
authors.initials: A
authors.lastname: Cai
authors.forename: Chun-Mei
authors.initials: CM
authors.lastname: Wang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D005260:Female; D020128:Inhibitory Concentration 50; D008114:Liver Neoplasms, Experimental / Q000473:pathology*; D008116:Lizards; D008419:Materia Medica / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D051379:Mice; D009368:Neoplasm Transplantation; D011208:Powders; D011897:Random Allocation; D013154:Spleen / Q000187:drug effects; D013678:Technology, Pharmaceutical / Q000379:methods; D013950:Thymus Gland / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D008419:Materia Medica; D011208:Powders